Literature DB >> 15737099

Bayesian monitoring of clinical trials with failure-time endpoints.

Gary L Rosner1.   

Abstract

This article presents an aid for monitoring clinical trials with failure-time endpoints based on the Bayesian nonparametric analyses of the data. The posterior distribution is a mixture of Dirichlet processes in the presence of censoring if one assumes a Dirichlet process prior for the survival distribution. Using Gibbs sampling, one can generate random samples from the posterior distribution. With samples from the posterior distributions of treatment-specific survival curves, one can evaluate the current evidence in favor of stopping or continuing the trial based on summary statistics of these survival curves. Because the method is nonparametric, it can easily be used, for example, in situations where hazards cross or are suspected to cross and where relevant clinical decisions might be based on estimating when the integral between the curves might be expected to become positive and in favor of the new but toxic therapy. An example based on an actual trial illustrates the method.

Mesh:

Substances:

Year:  2005        PMID: 15737099     DOI: 10.1111/j.0006-341X.2005.031037.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  Suspension of accrual in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2015-01-07       Impact factor: 2.486

2.  A Product Partition Model With Regression on Covariates.

Authors:  Peter Müller; Fernando Quintana; Gary L Rosner
Journal:  J Comput Graph Stat       Date:  2011-03-01       Impact factor: 2.302

3.  Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.

Authors:  Lili Zhao; Jeremy M G Taylor; Scott M Schuetze
Journal:  Stat Med       Date:  2012-02-23       Impact factor: 2.373

4.  Bayesian Nonparametric Inference - Why and How.

Authors:  Peter Müller; Riten Mitra
Journal:  Bayesian Anal       Date:  2013       Impact factor: 3.728

5.  Bayesian nonparametric nonproportional hazards survival modeling.

Authors:  Maria De Iorio; Wesley O Johnson; Peter Müller; Gary L Rosner
Journal:  Biometrics       Date:  2009-02-04       Impact factor: 2.571

6.  A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.

Authors:  Jian Wang; Junsheng Ma; Chunyan Cai; Naval Daver; Jing Ning
Journal:  Stat Med       Date:  2021-06-07       Impact factor: 2.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.